Arena Pharmaceuticals, Inc.

Neurocrine Biosciences, Inc.

Sanofi

Scott Stirn

Anthony C Blackburn

Anna Shifrina

Robert M Jones

Daniel J Buzard

Jaimie Karyn Rueter

Sangdon Han

Sun Hee Kim

Brett Ullman

Xiuwen Zhu

Juerg Lehmann

Zezhi Jesse Shao

Yun Shan

Jeanne V Moody

Michael E Morgan

Andrew J Grottick

Libo Yang

Woo Hyun Yoon

Michael D Morgan

Tawfik Gharbaoui

Nicole Harriott

Thomas O Schrader

Donald Nicholas Hettinger

William Lucas Betts, Iii

Edward A Lally

Shawn Branum

Michelle Kasem

Benjamin R Johnson

Nicholas Pagano

Gordon Raphael Loewen

John P Williams

Kingsley Iyoha

Brian M Cochran

Christina Marie Costa

Stacy Parks

Anthony D Vickery

Kristie M Downing

Graeme Taylor

Ayanda Ngwenya-Jones

Robert H Farber

Jean L Chan

Anne Charlier

Lev Alexander Zegelman

John Lloyd Tucker

Jackie Le

David Kucera

Max A Mellmer

Gurvinder Singh Mehton

Neil J Ashweek

Xiaoping Zhang

Brian Sayers

Nagdeep Giri

Provided herein are compounds of the following Formula (I): or a pharmaceutically acceptable salt thereof. Methods for treating a diseases, disorders, or symptom by antagonizing muscarinic receptors, including specifically antagonizing muscarinic receptor 4 (M4), are also provided.

Muscarinic receptor 4 antagonists and methods of use

The present invention relates to methods for weight management that utilize modified-release dosage forms comprising (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts and crystalline forms thereof. The present invention further relates to (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine salts, crystalline forms thereof and modified-release dosage forms comprising them.

Modified-release dosage forms of 5-HTagonists useful for weight management

[object Object]

The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases. 

Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders

Salts of the 5-HT-receptor agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, and dosage forms comprising them that are useful for, inter alia, weight management.

Salts of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine with optically active acids, and pharmaceutical compositions comprising them that are useful for, inter alia, weight management.

Salts of lorcaserin with optically active acids

The present invention relates to salts, processes, and process intermediates useful in the preparation of (R)-2-(9-chloro -7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid of Formula (Ia), salts, and crystalline forms thereof. The compound (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid has been identified as an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis). 

Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof

Provided are certain solvates of 3-methoxy-N-[3-(2-methyl-2H-pyrazol-3-yl)-4-(2-morpholin-4-yl-ethoxy)-phenyl]-benzamide or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions comprising such solvates and methods for their use.

The present invention relates to certain substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives of Formula (Ia): and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, microbial infections or diseases and viral infections or diseases.

Growing community of inventors

San Diego, CA, United States of America

Scott Stirn